Analysed ALLARITY THERAPEUTICS INC (ALLR:NASDAQ) News Sources
Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress
31-03-2026
yahoo.com
Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization
06-03-2026
yahoo.com
Allarity Therapeutics Doses First Patients in VA-Funded Phase 2 Trial Focused on Small Cell Lung Cancer with High Unmet Need
18-02-2026
yahoo.com
Allarity Therapeutics announces that its collaborative Phase 2 trial with the United States Veteran’s Administration Combining Stenoparib with Temozolomide in Relapsed Small Cell Lung Cancer is Now Open for Enrollment
03-02-2026
yahoo.com
Allarity Therapeutics Provides Third Quarter 2025 Financial Results and Provides Business Updates
14-11-2025
yahoo.com
Allarity Therapeutics Presents New Phase 2 Clinical Data for Stenoparib/2X-121 Showing Landmark Median Overall Survival Has Now Surpassed 25 Months
22-09-2025
yahoo.com
What is the current price of ALLARITY THERAPEUTICS INC (ALLR:NASDAQ)?
The current price of ALLARITY THERAPEUTICS INC (ALLR:NASDAQ) is $1.27.
ALLARITY THERAPEUTICS INC (ALLR:NASDAQ) absolute price change since previous trading day?
The absolute price change of ALLARITY THERAPEUTICS INC (ALLR:NASDAQ) since the previous trading day is $0.12.
ALLARITY THERAPEUTICS INC (ALLR:NASDAQ) percentage price change since previous trading day?
The percentage price change of ALLARITY THERAPEUTICS INC (ALLR:NASDAQ) since the previous trading day is 10.4348%.
What is the most recent average sentiment score for ALLARITY THERAPEUTICS INC (ALLR:NASDAQ)?
The most recent average sentiment score for ALLARITY THERAPEUTICS INC (ALLR:NASDAQ) is 87 out of 100.
What is the most recent average sentiment for ALLARITY THERAPEUTICS INC (ALLR:NASDAQ)?
The most recent sentiment for ALLARITY THERAPEUTICS INC (ALLR:NASDAQ) is .
SEC-8K** Filing Available For ALLARITY THERAPEUTICS INC (ALLR:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.